The Role of Thyroid Disease and Other Biomarkers in Invasive Breast Cancer: A 3-year Retrospective Comparative Study
References
- World Health Organization. Breast Cancer.
https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ Available on 24.03.2020 - Ferlay, J., Soerjomataram, I., Dikshit, R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386
- Hoon Tan P1, Ellis I2, Allison K3, Brogi E4, Fox SB5, Lakhani S6, Lazar AJ7, Morris EA4, Sahin A7, Salgado R8, Sapino A9,10, Sasano H11, Schnitt S12, Sotiriou C13, van Diest P14, White VA15, Lokuhetty D15, Cree IA15; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the breast. Histopathology. 2020
- Agarwal I. Blanco L. WHO classification of breast tumors. 2020
https://www.pathologyoutlines.com/topic/breastmalignantwhoclassification.html - Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.
- Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95–120.
- Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open. 2017;5(3):E734–E739.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182
- Hercbergs A, Mousa SA, Leinung M, Lin HY, Davis PJ. Thyroid Hormone in the Clinic and Breast Cancer. Horm Cancer. 2018;9(3):139–143. doi:10.1007/s12672-018-0326-9
- Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20;304(15):1684–92
- Villa NM, Li N, Yeh MW, Hurvitz SA, Dawson NA, Leung AM. SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS. Endocr Pract. 2015;21(9):1040–1045.
- American Cancer Society. Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society, Inc. 2019
- Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran. 2016;30:369.
- Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S. et al. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J cancer. 2009;101(1):32–7
- Calderon-Garciduenas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldana HA. Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud publica de Mexico. 2005;47(2):110–5
- Tereschenko IV, Basham VM, Ponder BA, Pharoah PD. BRCA1 and BRCA2 mutations in Russian familial breast cancer. Human mutation. 2002;19(2):184
- Ayub SG, Rasool S, Ayub T, Khan SN, Wani KA, Andrabi KI. Mutational analysis of the BRCA2 gene in breast carcinoma patients of Kashmiri descent. Mol Med Reports. 2014;9(2):749–53.
- Balraj P, Khoo AS, Volpi L, Tan JA, Nair S, Abdullah H. Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients. Singapore Med J. 2002;43(4):194–7.
- Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B. et al. A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast cancer res treat. 2005;91(2):203–5
- Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.
- Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 2000;18(21 Suppl):107s–12s.
- Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC cancer. 2008;8:146.
- Loboda AP, Adonin LS, Zvereva SD, et al. BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers. Int J Mol Sci. 2023;24(5):4982.
- Dutil J, Colon-Colon JL, Matta JL, Sutphen R, Echenique M. Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer genetics. 2012;205(5):242–8.
- Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2015;8:23–31
- Wang, J., Li, B., Luo, M. et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Sig Transduct Target Ther 9, 83 (2024).
https://doi.org/10.1038/s41392-024-01779-3 - Toikkanen S, Pylkkänen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997;76(9):1234–1240.
- Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–1747. doi:10.1093/annonc/mdr304
- Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102–109.
- Balic M, Thomssen Ch, Wuerstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast care. 2019; 14: 103–110
- He L, Lv Y, Song Y, Zhang B. The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity. Cancer Manag Res. 2019;11:5765–5775
- Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. International Journal of Molecular Sciences. 2024; 25(2):1064.
https://doi.org/10.3390/ijms25021064 - Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.
- Björnström L1, Sjöberg M. Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes. Mol Endocrinol. 2005 Apr;19(4):833–42
- Lu Q1, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor α. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17126–31
- Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022;13:839005. Published 2022 Aug 18. doi:10.3389/fendo.2022.839005.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.
- Song F, Zhang J, Li S, et al. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017;10:4859–4867.
- Yao N, Song Z, Wang X, Yang S, Song H. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. J Breast Cancer. 2017;20(2):160–169.
- Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022;16:305–314. Published 2022 Jan 26. doi:10.2147/DDDT.S336643
- Scholzen T, Gerdes J (March 2000). “The Ki-67 protein: from the known and the unknown”. J Cell Phys. 182 (3): 311–22
- Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504.
- Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–552.
- Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021;13(17):4455. Published 2021 Sep 3. doi:10.3390/cancers13174455.
- Fariduddin MM, Haq N, Bansal N. Hypothyroid Myopathy. [Updated 2024 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK519513/ - Sogaard M, Farkas DK, Ehrenstein V, Jorgensen JO, Dekkers OM, Sorensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016;174(4):409–414.
- Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid Hormone Causes Mitogen-Activated Protein Kinase-Dependent Phosphorylation of the Nuclear Estrogen Receptor. Endocrinology 145(7):3265–3272
- Falstie-Jensen, A.M., Kjærsgaard, A., Lorenzen, E.L. et al. Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study. Breast Cancer Res 21, 44 (2019).
- Ortega-Olvera, C., Ulloa-Aguirre, A., Ángeles-Llerenas, A. et al. Thyroid hormones and breast cancer association according to menopausal status and body mass index. Breast Cancer Res 20, 94 (2018).
- So CL, Saunus JM, Roberts-Thomson SJ, Monteith GR. Calcium signalling and breast cancer. Semin Cell Dev Biol. 2019;94:74–83. doi:10.1016/j.semcdb.2018.11.001
- Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States) Cancer Causes Control. 2005;16:83–95
- Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. Mol Cell Endocrinol. 2017;453:36–45. doi:10.1016/j.mce.2017.04.008.
- Almquist M, Manjer J, Bondeson L, Bondeson AG. Serum calcium and breast cancer risk: results from a prospective cohort study of 7,847 women. Cancer Causes Control. 2007;18:595–602
- Sprague BL, Skinner HG, Trentham-Dietz A, Lee KE, Klein BE, Klein R. Serum calcium and breast cancer risk in a prospective cohort study. Ann Epidemiol. 2010;20(1):82–85.
Language: English
Submitted on: Dec 25, 2024
Accepted on: Aug 27, 2025
Published on: Jul 8, 2026
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Alexandrina Nikova, Spyridon Plakas, Vasilios Tselepidis, Pinelopi Vlotinou, Helena Michalopoulou, Anna Tsiakiri, Loukas Karelis, Christos Valavanis, Eustathios Vlachakis, Maria Kyriazi, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.